FMI
Foundation Medicine is a precision oncology company focused on biomarker-driven cancer care, offering comprehensive genomic profiling and companion diagnostic tests to guide treatment decisions for patients. It provides a portfolio of diagnostic tests and biopharma services, including clinical development support and data-driven decision tools, with a global footprint and emphasis on EMR integrations to streamline clinical workflows. The company operates primarily in the United States, serving healthcare professionals, patients, and biopharma partners, and highlights resources such as a Knowledge Center and provider/patient education. Its tests, including FoundationOne CDx and FoundationOne Liquid CDx, aim to identify actionable genomic alterations to inform targeted therapies and immunotherapies.
No recent news for this company.
No recent deals for this company.